FDA Approves Bemotrizinol, First New Sunscreen Ingredient in 25 Years
FDA approves bemotrizinol, the first new sunscreen ingredient approved in 25 years.
Event / Science
FDA Sunscreen Ingredient Approval
The FDA approved bemotrizinol as the first new sunscreen active ingredient permitted in the U.S. market in over 25 years. The ingredient, previously used safely in Europe since 1999, will be marketed as Parsol Shield with an 18-month exclusivity period.
2 reported locations
Daily activity
0 articles0 articles
2026-08-16 to 2026-11-13 · UTC publication dates
Coverage begins 10 Jun, 02:06 UTC
Follow the documented timeline or explore the related reporting.
What happened
FDA approves bemotrizinol as first new sunscreen ingredient in over 25 years
The U.S. Food and Drug Administration approved bemotrizinol on Tuesday, June 9, 2026, marking the first approval of a new sunscreen active ingredient in more than 25 years. Bemotrizinol is a broad-spectrum ultraviolet filter that protects against both UVA and UVB rays while causing minimal skin irritation and absorption. The ingredient has been safely used in Europe since 1999 but was not previously authorized for use in the United States.
Bemotrizinol to be marketed under brand name Parsol Shield by DSM Nutritional Products
Dutch manufacturer DSM Nutritional Products will initially sell bemotrizinol in the United States under the brand name Parsol Shield, with an expected launch later in 2026. The product will have an 18-month exclusivity period before other manufacturers are permitted to use the ingredient.
Bemotrizinol first ingredient approved under streamlined FDA process from 2020
Bemotrizinol is the first sunscreen ingredient to be approved through a streamlined approval process authorized by Congress in 2020, designed to expedite the updating of FDA's lists of safe nonprescription drug ingredients. Bemotrizinol was originally filed with the FDA for review in 2005 after receiving authorization from European authorities in 1999.
Read the coverage
2 alternative perspectives